The type taxonomy of the Isoniazid market distinguishes five sub‑segments: monotherapy, fixed‑dose combinations (FDCs), extended‑release formulations, pediatric‑specific dosage forms, and the generic versus branded split. Monotherapy remains the baseline product, primarily used in preventive protocols; its price sensitivity limits margin but sustains a stable volume share of roughly 25 % of total units sold. Fixed‑dose combinations, most commonly paired with rifampicin, isoniazid‑pyrazinamide‑ethambutol or newer regimens, capture about 40 % of revenue because they simplify adherence and are favored by national TB programs. Extended‑release tablets, designed to reduce dosing frequency, occupy a niche (~5 %) yet command premium pricing, reflecting ongoing clinical‑trial investment. Pediatric‑specific formulations—dispersible tablets and syrups—represent an emerging 10 % slice, driven by WHO child‑friendly recommendations and rising demand in high‑burden regions. Finally, the generic‑branded dichotomy accounts for the remaining 20 % of market value, where generic competition depresses price while branded products preserve higher margins through patented delivery technologies. Collectively, these type segments delineate the structural drivers of Isoniazid market growth and inform strategic positioning within the broader market taxonomy.
